Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence.

F1000Res · 2019 · PMC6820822 · PMID 31700615

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

difference was apparentno p-value reported

However, no significant difference was apparent between placebo treated and IL-1Ra treated patients for these factors, suggesting IL-1Ra treatment exerts no effects additional to stroke.

also in 830 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.